| |
| |
| |
| Methodology of prophylactic trials1 | |
| |
| |
| |
| Principles of preventive pharmacotherapy in primary headache | |
| |
| |
| |
| |
| Methodology and implementation of systematic reviews | |
| |
| |
| |
| |
| Adverse events, equally important as efficacy as an outcome parameter? | |
| |
| |
| |
| |
| Methodology of prophylactic trials: discussion summary | |
| |
| |
| |
| |
| Prophylactic drugs I | |
| |
| |
| |
| Key issues in the methodology of prophylactic migraine trials | |
| |
| |
| |
| |
| Migraine prophylaxis: a pharmacoepidemiological study of practices used by general practitioners and neurologists in France | |
| |
| |
| |
| |
| Preventive treatment of migraine headache with rofecoxib | |
| |
| |
| |
| |
| Prophylactic treatment and course of the disease in headache associated with sexual activity | |
| |
| |
| |
| |
| Propylactic drugs I: discussion summary | |
| |
| |
| |
| |
| Prophylactic drugs II | |
| |
| |
| |
| Prevention of migraine: betablockers and amine agonists: efficacy | |
| |
| |
| |
| |
| Antiepileptic drugs in migraine prevention | |
| |
| |
| |
| |
| Mechanism(s) of action of the antiepileptic drugs Valproic Acid, Gabapentin, and Topiramate: implications for the prophylactic management of migraine | |
| |
| |
| |
| |
| Experience with topiramate in patients with refractory migraine | |
| |
| |
| |
| |
| Topiramate in a selective group of therapy refractory headache patients | |
| |
| |
| |
| |
| Prophylactic drugs II: discussion summary | |
| |
| |
| |
| |
| Prophylactic Drugs III | |
| |
| |
| |
| Efficacy of antidepressants in headache prophylaxis | |
| |
| |
| |
| |
| Antidepressants: mechanisms of action | |
| |
| |
| |
| |
| Other prophylactic anti-migraine agents: riboflavin feverfew, magnesium, botulinum toxin and calcium antagonists | |
| |
| |
| |
| |
| Treatment of chronic tension type headache with mirtazapine | |
| |
| |
| |
| |
| Botulinum toxin type A in the treatment of refractory headache | |
| |
| |
| |
| |
| Botulinum toxin A in the prophylaxis of migraine - a double-blind, placebo-controlled, randomised study comparing frontal and cervical injection | |
| |
| |
| |
| |
| Description of a prospective, multicenter observational study of headache treatment with Botulinum toxin type A: the program to assess treatment strategies (PATS) registry | |
| |
| |
| |
| |
| Mechanisms of the antinociceptive effect of subcutaneous BOTOX: inhibition of peripheral and central nociceptive processing | |
| |
| |
| |
| |
| Survey on expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment | |
| |
| |
| |
| |
| Prophylactic treatment of migraine with lomerizine hydrochloride | |
| |
| |
| |
| |
| Prophylactic drugs III: discussion summary | |
| |
| |
| |
| |
| New Targets I | |
| |
| |
| |
| Antagonising peripheral sensitisation in migraine | |
| |
| |
| |
| |
| New possibilities for antimigraine therapy via 5-HT receptors? | |
| |
| |
| |
| |
| Dihydroergotamine interaction with 5-HT2 receptors and its relevance to migraine | |
| |
| |
| |
| |
| Migraine prophylaxis with drugs | |
| |